Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,462.86 -6.44 (-0.12%) Dow
39,075.23 -36.93 (-0.09%) Nasdaq
17,745.41 +27.75 (+0.16%) Bitcoin USD
61,732.49 -30.26 (-0.05%) CMC Crypto 200
1,277.74 -6.05 (-0.47%)
ITCI Aug 2024 75.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:47PM EDT. Market open.
| Previous close | 5.4000 |
| Open | 3.8000 |
| Bid | 2.5500 |
| Ask | 2.8000 |
| Strike | 75.00 |
| Expiry date | 2024-08-16 |
| Day's range | 3.1000 - 3.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 428 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.